Whole Genome Bisulfite Sequencing Market Size to Reach USD 1,068.5 million in 2032
The Whole Genome Bisulfite Sequencing Market size was USD 288.8 million in 2024 and is expected to register a revenue CAGR of 17.7% during the forecast period
April 01, 2024 – Increase in prevalence of cancer, neurological and cardiovascular disorders is a key driver driving whole genome bisulfite sequencing market revenue growth. According to the World Health Organization (WHO), globally, over 3 billion people suffer from a neurological disorder. Access to therapy varies greatly, and over 80% of neurological deaths and health losses take place in low- and middle-income nations. Diabetic neuropathy was the fastest developing neurological disorder. Up to 50% of people with type 1 and type 2 diabetes have diabetic neuropathy, the most prevalent consequence of DM.
On February 2025, Illumina, Inc. has unveiled a series of roadmap innovations, establishing the industry’s largest portfolio of omics solutions and sequencing applications. The solutions, which span genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software, will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions exceed industry standards for scale, accuracy, and reliability.
The challenge of data interpretation remains a significant barrier to market growth. One of the major issues in methylation detection methods is incomplete bisulfite treatment, which can lead to overestimation of methylation levels in a sample. Additionally, DNA degradation during extended incubation periods poses a challenge for bisulfite-based methylation studies. Sodium bisulfite treatment effectively converts the genome into three bases (A, G, and U/T), except for a small proportion of methylated cytosines, adding further complexity to the analysis.
Key Highlights:
- Instruments segment is expected to register the largest market share over the forecast period. The growth of the segment is driven by high-throughput, cost-efficient, and precise methylation sequencing. Innovations in NGS technologies and long-read sequencing are broadening research applications and boosting the integration of WGBS in clinical and translational research. Cutting-edge sequencing instruments allow researchers to explore methylation patterns in embryonic development and neurodegenerative diseases.
- Agricultural & plant epigenetics segment is expected to account for the fastest growth rate over the forecast period. Research on DNA methylation’s role in nutrient uptake and stress responses has highlighted its potential to improve nutrient use efficiency in crops, reducing dependence on chemical fertilizers. For example, in nitrogen-deficient environments, some plants enhance nitrogen absorption by altering the methylation patterns of essential genes, presenting a promising approach for developing nutrient-efficient crop varieties.
- North America accounted for the largest market revenue share in the whole genome bisulfite sequencing market in 2024 due to the increase in prevalence of cancer and technological advancements of whole genome bisulfite sequencing instruments and kits. On May 2022, Twist Bioscience Corporation, announced the release of the Twist Human Methylome Panel, a product that can advance applications in cancer metastasis, human development, and functional genetics. To find biologically important methylation markers, the panel can detect a strong, collected set of CpG sites, methylated cytosine, and guanine nucleic bases, across the human genome.
- Some major companies in the market report include CD Genomics, BGI, Eurofins Genomics, Thermo Fisher Scientific, Inc., Illumina, Inc., Zymo Research, QIAGEN, Agilent Technologies, Hologic Inc., New England Biolabs, Merck KGaA, Creative Biolabs, Nucleome Informatics, Singulomics Corporation, and Novogene Co., Ltd.
- On October 2023, Mayo Clinic and Oxford Nanopore Technologies, a firm that provides a new generation of nanopore-based molecular sensing technologies, have announced a multi-year joint development agreement to create novel clinical diagnostics for diseases and improve patient care. Mayo Clinic and Oxford Nanopore have identified various possibilities for advancement, ranging from translational research in human genetics to the identification of genetic predisposition to cancer.
Unlock the key to transforming your business strategy with our Whole Genome Bisulfite Sequencing Market insights:
Navistrat Analytics has segmented whole genome bisulfite sequencing market based on product and service, application, and end-use:
- Product and Service Outlook (Revenue, USD Million; 2022-2032)
- Instruments
- Reagents & Kits
- DNA Extraction & Purification Kits & Reagents
- PCR & Amplification Kits & Reagents
- Sequencing Kits & Reagents
- Bisulfite Conversion Kits & Reagents
- Library Preparation Kits & Reagents
- Software
- DNA Methylation Analysis Tools
- Cloud-Based Bioinformatics Solutions
- Services
- Application Outlook (Revenue, USD Million; 2022-2032)
- Epigenetics Research
- Cancer Research & Oncology
- Developmental Biology
- Neurological Disorders Research
- Agricultural & Plant Epigenetics
- Infectious Disease Research
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Academic & Research Institutions
- Biotechnology & Pharmaceutical Companies
- Clinical & Diagnostic Laboratories
- Contract Research Organizations (CROs)
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America